^
Association details:
| Biomarker: | EGFR E746_A750del |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Excerpt:
Characteristics of patients sensitive to gefitinib (G) and erlotinib (E)....Four of the exon 19 deletion mutations were the same as the previously described del E746-A750….Deletion mutations in exon 19 of EGFR from NSCLCs sensitive to TKIs, gefitinib (G) or erlotinib (E).
DOI:
10.1073/pnas.0405220101
Source:
Title:
Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study
Excerpt:
This open-label phase II trial enrolled stage III/IV NSCLC patients who had progressive disease after at least one prior platinum-based chemotherapy regimen. Erlotinib was administered at a dose of 150 mg/d orally until disease progression or intolerable toxicity....Three patients who had deletion mutations on exon 19 (del E746-A750 or del S752-I759) exhibited objective response.
DOI:
https://doi.org/10.1097/JTO.0b013e31818d6702
Source:
Title:
Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272
Excerpt:
Consistent with previous reports, H3255 (EGFR L858R) and HCC827 (EGFR E746_A750del) were sensitive to erlotinib treatment ( 15, 16), with IC50 values of 0.031 and 0.003 μmol/L, respectively ( Fig. 1A).
DOI:
10.1158/0008-5472.CAN-06-0971
